TACR3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Talnetant (SCHEMBL74220)	1.00	20/20
Talnetant (SCHEMBL74221)	1.00	20/20
SCHEMBL321685	1.00	20/20
SCHEMBL321700	1.00	20/20
SCHEMBL322188	1.00	20/20
SCHEMBL325826	1.00	20/20
SCHEMBL325879	1.00	20/20
SCHEMBL325894	1.00	20/20
SCHEMBL326461	1.00	20/20
SCHEMBL326560	1.00	20/20
SCHEMBL326622	1.00	20/20
SCHEMBL326651	1.00	20/20
SCHEMBL326693	1.00	20/20
SCHEMBL326821	1.00	20/20
SCHEMBL327214	1.00	20/20
SCHEMBL327311	1.00	20/20
SCHEMBL327382	1.00	20/20
SCHEMBL327427	1.00	20/20
SCHEMBL327565	1.00	20/20
SCHEMBL326086	0.86	20/20

Clinical trials — most relevant to TACR3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
The Effect of Pre-operative Electrical Stimulation on Peripheral Nerve Regeneration.	PHASE2/PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease	PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics	PHASE2	WITHDRAWN
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ	PHASE1	COMPLETED
Precision Medicine for Nociception, Sngception and Proprioception.	nan	RECRUITING
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Urinary Cytokines in Patients With Overactive Bladder (OAB)	nan	COMPLETED
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial	nan	UNKNOWN
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
Renal Transporters After Renal Transplantation	nan	UNKNOWN
Genetics and Cardiovascular Reactivity in Young Twins	nan	COMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TACR3 binder may also engage these)

Protein	Name	Similarity
O97512	—	0.992	O97512 →
P47937	—	0.991	P47937 →
P16177	—	0.991	P16177 →
P30098	—	0.984	P30098 →
Q98982	—	0.973	Q98982 →
TACR1	Substance-P receptor	0.963	landscape →
P30547	—	0.960	P30547 →
Q5DUB3	—	0.959	Q5DUB3 →
P30548	—	0.959	P30548 →
Q5DUB1	—	0.955	Q5DUB1 →
P14600	—	0.955	P14600 →
P30975	—	0.955	P30975 →
P70031	—	0.947	P70031 →
Q9WTV9	—	0.947	Q9WTV9 →
Q64077	—	0.946	Q64077 →
Q9WTV8	—	0.946	Q9WTV8 →
O97772	—	0.945	O97772 →
P05363	—	0.945	P05363 →
O08786	—	0.943	O08786 →
Q5D0K2	—	0.943	Q5D0K2 →
CCKAR	Cholecystokinin receptor type A	0.942	landscape →
P30551	—	0.941	P30551 →
Q5DUB2	—	0.940	Q5DUB2 →
Q90352	—	0.939	Q90352 →
P48043	—	0.938	P48043 →
TACR2	Substance-K receptor	0.938	landscape →
P70536	—	0.937	P70536 →
Q9TTQ9	—	0.937	Q9TTQ9 →
P30560	—	0.937	P30560 →
AVPR1A	Vasopressin V1a receptor	0.935	landscape →